Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

Exclusion Criteria

• •Patients who have a contraindication to dupilumab according to the country-specific prescribing information label.
• •Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from completing the schedule of visits and assessments.
• •Patients currently participating in any interventional clinical trial.
• •Prior use of dupilumab within 6 months of the screening visit, or within 6 months of the baseline visit if screening and baseline occur on the same day.